Adbiotech
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Adbiotech develops antibody-based biological products designed to prevent and treat diseases in livestock, aquaculture, and humans, offering alternatives to conventional vaccines and antibiotics.
Its products target farmers, aquaculture operators, and the broader animal-health supply chain. Listed on KOSDAQ, Korea's tech and small-cap board, the company's core platform is IgY technology, which extracts disease-fighting antibodies from egg yolk to create natural passive-immune preparations against viruses, bacteria, and parasites.
Summary is AI-generated and may contain errors · figures from DART filings
Adbiotech in five facts
What does Adbiotech do?
Adbiotech develops antibody-based biological products designed to prevent and treat diseases in livestock, aquaculture, and humans, offering alternatives to conventional vaccines and antibiotics.
Where is Adbiotech listed and in which sector?
Adbiotech (Korean name: 애드바이오텍) trades under KRX code 179530 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Adbiotech?
Its market capitalisation was US$50.4M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Adbiotech's latest annual revenue and operating profit?
For fiscal year 2025, Adbiotech reported revenue of US$9.7M, an operating loss of US$2.6M and a net loss of US$2.5M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was up 15.8% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on large shareholdings (5% rule) (abbreviated)Sep 23
- Report on large shareholdings (5% rule) (abbreviated)Sep 22
- DisclosureSep 8
- DisclosureSep 4
- [Amended] Material event report (convertible bonds)
Adbiotech updated the terms of convertible bonds to raise US$4.06M, about 8.7% of its market value.
Capital raise · Sep 3 · 7 versions - [Amended] Material event report (convertible bonds)
Adbiotech updated the terms of convertible bonds to raise US$1.48M, about 3.2% of its market value.
Capital raise · Sep 3 · 9 versions - [Amended] Material event report (decision to sell own convertible bonds)
Adbiotech Co., Ltd. amends its March 27, 2026 decision to sell its own 7th-series convertible bonds, revising the payment schedule to add an interim payment and change the final payment date from September 3, 2026 to September 8, 2026, with an interim payment of US$837K on September 3 and the final payment of US$1.48M on September 8, 2026; total sale price is US$2.43M for bonds with face value US$2.21M sold to K Polaris Investment Partnership.
Capital raise · Sep 3 · 5 versions - DisclosureSep 1
- [Attachment amended] Material event report (equity acquisition)M&A · Aug 24
- Completion report on merger, etc. (asset transfer)
Adbiotech Co., Ltd. completed, on July 3, 2026, its acquisition of 181,269 common shares (12.28% voting interest) of Onheal Co., Ltd. for US$6.46M in cash, as disclosed in its July 3, 2026 material event report.
M&A · Jul 3 - Material event report (equity acquisition)
Adbiotech Co., Ltd. decided on July 3, 2026 to acquire 181,269 common shares (12.28% stake) of Onheal Co., Ltd. for US$6.46M in cash from Hiworks Co., Ltd. and one other party, for business diversification.
M&A · Jul 3 - Change of largest shareholder of the nominee entity that is the largest shareholderOwnership change · Jun 4
- [Amended] Material event report (rights offering)
Adbiotech updated the terms of a private placement (third-party allotment) to raise US$8.75M, about 21.2% of its market value.
Capital raise · Jun 4 - [Amended] Material event report (rights offering)
Adbiotech updated the terms of convertible bonds to raise US$8.93M, about 21.2% of its market value.
Capital raise · May 27 - [Amended] Material event report (rights offering)
Adbiotech updated the terms of convertible bonds to raise US$8.99M, about 21.2% of its market value.
Capital raise · May 14 - [Amended] Material event report (rights offering)
Adbiotech updated the terms of convertible bonds to raise US$9.11M, about 21.2% of its market value.
Capital raise · Apr 10 - Material event report (decision to redeem own convertible bonds early)Capital raise · Mar 25
- [Amended] Material event report (rights offering)
Adbiotech updated the terms of convertible bonds to raise US$9.13M, about 21.2% of its market value.
Capital raise · Mar 13 - [Amended] Material event report (convertible bonds)
Adbiotech updated the terms of convertible bonds to raise US$2.59M, about 5.6% of its market value.
Capital raise · Feb 20 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Adbiotech reported consolidated results for FY2025: revenue of US$8.82M (+15.81% year on year), an operating loss of US$2.37M and a net loss of US$3.39M.
Earnings · Feb 9 - [Amended] Material event report (convertible bonds)
Adbiotech updated the terms of convertible bonds to raise US$2.72M, about 6.1% of its market value.
Capital raise · Feb 6 - Material event report (decision to redeem own convertible bonds early)Capital raise · Jan 29
- [Amended] Material event report (rights offering)Capital raise · Jan 16
- [Amended] Material event report (rights offering)Capital raise · Jan 13
- Material event report (decision to redeem own convertible bonds early)Capital raise · Jan 12